- Home
- ATOS vs CVM Comparison
ATOS vs CVM Comparison
Compare ATOS & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATOS | CVM |
|---|---|---|
| Founded | 2009 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.2M | 32.4M |
| IPO Year | 2010 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ATOS | CVM |
|---|---|---|
| Price | $5.01 | $3.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $31.67 | N/A |
| AVG Volume (30 Days) | ★ 89.0K | 39.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,758.00 | ★ $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $0.53 | $0.18 |
| 52 Week High | $7.56 | $13.48 |
Technical Indicators
Market Signals| Indicator | ATOS | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 66.34 | 34.46 |
| Support Level | $0.68 | $3.34 |
| Resistance Level | $5.12 | $6.82 |
| Average True Range (ATR) | 0.35 | 0.35 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 72.46 | 14.60 |
Price Performance
Historical ComparisonAbout ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.